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CM2 is the second membrane protein of inﬂuenza C virus and possesses a conserved motif for N-
glycosylation. To investigate the role(s) of CM2 glycosylation in the virus replication, we generated rN11A,
a recombinant inﬂuenza C virus lacking the glycosylation site. The rN11A virus grew less efﬁciently than
the wild-type (WT) virus, although the biochemical characteristics of the mutant CM2 were similar to
those of authentic CM2. The amount of the genome (GFP-vRNA) in the CM2-N11A-virus-like particles
(VLPs) was 13% of that found in WT-VLPs. The incoming GFP-vRNA was less efﬁciently transported to the
nucleus in CM2-N11A-VLP-infected cells than WT-VLP-infected cells, leading to the reduced reporter gene
expression in CM2-N11A-VLP-infected cells. Thus the glycosylation of CM2 is required for efﬁcient
replication of inﬂuenza C virus, and the obtained ﬁndings conﬁrmed and extended the previous
observation that CM2 is involved in the genome packaging and uncoating processes.
& 2012 Elsevier Inc. All rights reserved.Introduction
Inﬂuenza C virus has seven single-stranded RNA segments of
negative polarity and these segments encode the nine virus
proteins (Palese and Shaw, 2007). The RNA segment 6 (M gene)
of C/Ann Arbor/1/50 (AA/50) is 1180 nucleotides in length
(Muraki et al., 2007) and contains a single open reading frame
(positions 26–1150) that could encode a polypeptide (P42) of 374
amino acids (Hongo et al., 1994; Muraki and Hongo, 2010). The
predominant mRNA transcript of this RNA segment lacks a region
from nucleotides 754 to 981 and encodes a 242-amino acid
matrix (M1) protein (Hongo et al., 1994; Yamashita et al., 1988).
Unspliced mRNA of the gene is ﬁrst translated into P42, and then
it is cleaved by signal peptidase at an internal cleavage site,
generating M10 and CM2, which are composed of the N-terminal
259 amino acids and the C-terminal 115 amino acids of P42,
respectively (Hongo et al., 1994, 1999; Pekosz and Lamb, 1998).
CM2 is a type III integral membrane protein that is oriented in
membranes with a 23-amino-acid N-terminal extracellular domain,
a 23-amino-acid transmembrane domain and a 69-amino-acid C-
terminal cytoplasmic domain (Hongo et al., 1997; Pekosz and Lamb,
1997). It forms disulﬁde-linked dimers and tetramers, and is
posttranslationally modiﬁed by palmitoylation and phosphoryla-
tion (Hongo et al., 1994; Li et al., 2001; Tada et al., 1998). It is
also modiﬁed by N-glycosylation on an asparagine at residue 11,
and, as a result, three forms of CM2 with different electrophoretic
mobilities (CM2o, CM2a, and CM2b) are detected in infected cellsll rights reserved.
. Muraki).(Hongo et al., 1997; Pekosz and Lamb, 1997). A mannose-rich oli-
gosaccharide core is added to unglycosylated CM2o (Mr E16,000)
to form CM2a (Mr E18,000), and the maturation of the carbo-
hydrate chain from the high mannose type to the complex type
converts CM2a into CM2b (Mr 22,000–30,000), the latter of which is
modiﬁed by addition of polylactosaminoglycan.
To clarify the role(s) of CM2 in inﬂuenza C virus replication
cycle, several experiments have been carried out. Electrophysio-
logical analyses showed that CM2 forms a voltage-activated ion
channel permeable to Cl- (Hongo et al., 2004). When co-expressed
with a pH-sensitive hemagglutinin (HA) of inﬂuenza A virus, the
CM2 protein has a capacity to reduce the acidity of the exocytic
pathway (Be´takova and Hay, 2007). The CM2 protein expressed
from cDNA in 293T cells could alter cytoplasmic pH (Stewart and
Pekosz, 2012). A recent study using CM2-deﬁcient VLPs suggested
the involvement of CM2 in the genome packaging and uncoating
processes (Furukawa et al., 2011), although the role(s) of CM2 in
the context of virus replication remains to be clariﬁed.
Analyses of a number of CM2 mutants expressed in COS-1 and
HeLa cells revealed the positions of the amino acids involved in
the posttranslational modiﬁcations (Li et al., 2001; Pekosz and
Lamb, 1997): an asparagine at residue 11 is an N-glycosylation
site, cysteines at residue 1, 6 and 20 are involved in disulﬁde bond
formation, a cysteine at residue 65 is palmitoylated, and serines at
residue 78, 103, 108 are phosphorylation sites. Evidence was
obtained that the N-glycosylation is not required for either the
formation of disulﬁde-linked multimers or transport to the cell
surface (Pekosz and Lamb, 1997) and that none of dimer- and
tetramer-formation, palmitoylation or phosphorylation is essen-
tial for the transport of CM2 to the cell surface (Li et al., 2001).
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did not affect transport and maturation of HEF, NP and M1 as well
as CM2 in virus-infected cells, and palmitoylation of CM2 was
dispensable to inﬂuenza C virus replication (Muraki et al., 2011).
Given these ﬁndings, posttranslational modiﬁcations of CM2 do not
appear to be involved in virus replication, although all of the amino
acids are conserved among inﬂuenza C virus strains examined to
date (Matsuzaki et al., 2003; Tada et al., 1997). In the present study,
therefore, we examined the effect of another posttranslational
modiﬁcation, N-glycosylation, on the inﬂuenza C virus replication.Results
Synthesis of CM2 in recombinant-infected cells
To investigate the effect of CM2 glycosylation on the inﬂuenza
C virus replication, we generated rN11A, a recombinant inﬂuenza
C virus lacking the CM2 glycosylation site. To ﬁrst examineFig. 1. (A) Synthesis of CM2 in virus-infected cells. HMV-II cells infected with rWT or rN
120 min. The cell lysates were immunoprecipitated with anti-CM2 serum, and the imm
16 h at 37 1C and analyzed by SDS-PAGE. (B) The infected cells were pulse-labeled with
were immunoprecipitated with either anti-M1 MAb (L2) or anti-CM2 serum and analy
infected with rWT or rN11A at an MOI of 0.001, and then incubated for up to 120 h. The v
cells. Data are expressed as the mean7standard deviation (SD) in three independent ex
nnpo0.01). (D) HMV-II cells infected with rWT or rT13A at an MOI of 0.001 were incub
were titrated, and the titers from three independent experiments are shown as open cir
statistically evaluated (nnpo0.01). (E) Pulse-chase experiments of virus-infected cells.
for the indicated periods (min). The lysates were immunoprecipitated with MAbs agaiwhether the CM2 protein lacking glycosylation is synthesized in
rN11A-infected cells, HMV-II cells infected with rWT or rN11A at an
MOI of 5 PFU/cell were subjected to radioimmunoprecipitation. As
shown in Fig. 1A, CM2 was synthesized in both rWT- and rN11A-
infected cells, and CM2 synthesized in the rN11A-infected cells was
conﬁrmed to be non-glycosylated form of CM2, since CM2 in the
rN11A-infected cells had the same gel mobility as CM2 treated with
N-glycanase in the rWT-infected cells. Furthermore, CM2 in the
rN11A-infected cells was not apparently degraded after 120-min
chase (Fig. 1B). Thus, the non-glycosylated CM2 synthesized in the
rN11A-infected cells was stable.
P42, encoded by a collinear transcript of the M gene, is cleaved
by signal peptidase to generate M10 and CM2 (Hongo et al., 1999;
Pekosz and Lamb, 1998). Fig. 1A showed that the band intensity of
P42 in rN11A-infected cells increased compared with that in rWT-
infected cells just after pulse-labeling (0 min). We therefore
measured and compared the band intensities of M1, P42 (P44)
and CM2. The ratio of M1 to (P42þCM2) just after pulse-labeling
was 0.8: 1.0 in rN11A-infected cells, which was equivalent to that11A were pulse-labeled with [35S]methionine for 20 min at 26 h p.i. and chased for
unoprecipitated proteins were digested with (þ) or without () N-glycanase for
[35S]methionine at 26 h p.i. and chased for the indicated periods (min). The lysates
zed by SDS-PAGE. (C) Growth kinetics of recombinant viruses. HMV-II cells were
irus yields in the culture media at the indicated times were titrated using LLC-MK2
periments. All comparisons between groups were statistically evaluated (npo0.05;
ated for up to 120 h. The virus yields in the culture media at 72, 96 and 120 h p.i.
cles (rWT) and closed triangles (rT13A). All comparisons between the groups were
The infected cells were pulse-labeled with [35S]methionine at 26 h p.i. and chased
nst HEF (J14), NP (H27) or M1 (L2) and analyzed by SDS-PAGE.
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difference was observed in the ratio of the amount of M1 to that
of (P42þCM2) just after pulse-labeling between rWT- and rN11A-
infected cells. In contrast, the ratio of CM2 to P42 in rN11A-
infected cells (1.0: 0.8) was much greater than that in rWT-
infected cells (1.0:0.08) (Fig. 1B). Taken together, these results
indicate that the amount of P42 synthesized in rN11A-infected
cells is virtually identical to that in rWT-infected cells and suggest
that the conversion of P42 into CM2 is delayed in rN11A-
infected cells.
Growth kinetics of recombinants
We next compared growth kinetics of the recombinant viruses.
The rWT or rN11A virus was infected to HMV-II cells at an MOI of
0.001 PFU/cell and incubated at 33 1C for 120 h in the presence of
trypsin (20 mg/ml). The viruses in the culture media at 12–120 h
p.i. were titrated on LLC-MK2 cells. As a result, the rN11A virus
grew less efﬁciently than did rWT (Fig. 1C).
To conﬁrm that the lack of glycosylation, not the amino acid
mutation, attenuates the virus, we generated another mutant
virus, rT13A, in which a threonine at residue 13 within a motif for
N-glycosylation (11-NNT-13) of CM2 was mutated to alanine. We
conﬁrmed that CM2 synthesized in the rT13A-infected HMV-II
cells was not glycosylated (data not shown). The growth of rT13A
in HMV-II cells was examined under the condition described
above, and as a result it was signiﬁcantly reduced by approxi-
mately 10-times compared with that of rWT (po0.01) (Fig. 1D).Fig. 2. Maturation and transport of CM2 in virus-infected cells. (A) HMV-II cells infecte
p.i. and chased for 120 min. The lysates were immunoprecipitated with anti-CM2 ser
expression of CM2. At 48 h p.i., mock- or virus-infected HMV-II cells were ﬁxed and
Arrowheads indicate the plasma membrane. Bar, 20 nm. (C) Localization of CM2 in th
reacted with anti-CM2 serum and FITC-conjugated anti-rabbit IgG, or anti-g-adaptin M
(D) Surface expression of HEF and CM2 in infected cells. The surface of the virus-infect
were precipitated with streptavidin–agarose. The precipitates (B) or whole cell lysates (LTherefore, we concluded that glycosylation of CM2 appears to
have some effect on the generation of infectious viruses in
cultured cells, and decided to use the rN11A virus in the
subsequent experiments.
Synthesis of HEF, NP and M1 in infected cells
The major virus proteins synthesized in virus-infected cells
were examined. HMV-II cells infected with rWT or rN11A at an
MOI of 5 PFU/cell were pulse-labeled with [35S]methionine for
20 min at 26 h p.i. and chased for 60–240 min (Fig. 1E). The cell
lysates were immunoprecipitated with the MAbs against HEF
(J14), NP (H27) and M1 (L2), and analyzed by SDS-PAGE. The
synthesis and maturation of the HEF, NP and M1 proteins
exhibited no signiﬁcant differences between the rWT- and
rN11A-infected cells.
Maturation and transport of CM2 in infected cells
To examine whether the lack of glycosylation of CM2 affects its
multimer formation, the immunoprecipitated CM2 protein labeled
with [35S]methionine were treated with N-glycanase and analyzed
by SDS-PAGE under non-reducing conditions (Fig. 2A). The bands
corresponding to monomer (M), dimer (D) and tetramer (T) were
detected both in the rWT- and rN11A-infected cells, although the
origin of a band detected in rN11A-infected cells (0 min, indicated
by triangle) is unknown.d with rWT or rN11A were pulse-labeled with [35S]methionine for 20 min at 26 h
um and analyzed by SDS-PAGE in the absence of 2-mercaptoethanol. (B) Surface
reacted with anti-CM2 serum. The cells were examined by confocal microscopy.
e trans-Golgi network. At 48 h p.i., mock- or virus-infected cells were ﬁxed and
Ab and Alexa Fluor 594 anti-mouse IgG. Right panels indicates merged images.
ed cells was biotinylated and then the cells were lysed. The biotinylated proteins
) were subjected to immunoblotting using anti-CM2 serum or anti-HEF MAb (S16).
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that the CM2 protein was expressed on the cell surface in both the
rWT- and rN11A-infected cells (Fig. 2B). Furthermore, immuno-
ﬂuorescence of rN11A-infected cells showed that CM2 intracel-
lular localization was not altered by loss of glycosylation (Fig. 2C).
The amount of CM2 expressed on the rN11A-infected cell surface
was comparable to that on rWT-infected cells (Fig. 2D), since
there was no apparent difference in the ratio of biotinylated CM2
(lane B) to the whole CM2 (lane L) between rWT- and rN11A-
infected cells. In Fig. 2D, an origin of E30 kDa band in rN11A-
infected cells is unknown. Taken together, these observations
indicate that glycosylation-deﬁcient CM2 is transported appro-
priately to the cell surface like authentic CM2.
Analyses of recombinant virus-infected cells
To further study the difference in the growth kinetics between
rWT and rN11A, a number of experiments were performed. First,
the rWT- or rN11A-infected HMV-II cells were analyzed by ﬂow
cytometry using anti-HEF MAb (J14). The histogram of the
infected cells showed that there were no differences in the
attachment and internalization between the rWT and rN11A
viruses (Fig. 3).
Takeda et al. (2002) showed the reduced synthesis of NP by
amantadine was observed in the MDCK cells infected with
amantadine-sensitive inﬂuenza A virus strains at the early phase
of infection. In the present study, to examine virus protein synthesis
at the early phase of infection, the rWT- or rN11A-infected cells
were labeled with [35S]methionine for 30 min every 2 h from 2 to
24 h p.i. and the respective cell lysates were analyzed by SDS-PAGE.
However, we could not detect any differences in the synthesis of NP
(data not shown). Thus we could not obtain evidence for the growth
difference between rWT and rN11A (Fig. 1C) by analyzing the
recombinant-infected cells.
Generation of inﬂuenza C VLPs possessing non-glycosylated CM2
The inﬂuenza C VLP generation system has been shown to be of
use to study the effect of mutation(s) on the virus replication
process (Furukawa et al., 2011). In the present study, therefore, we
generated N11A-VLPs, VLPs possessing non-glycosylated CM2, and
analyzed the VLPs, VLP-producing cells and VLP-infected cells.
Prior to the experiment, we re-evaluated the amount of pME18S/
Met-CM2-YA transfected to 293T cells since the efﬁciency of reporterFig. 3. Flow cytometry of HMV-II cells infected with recombinant viruses. HMV-II cel
incubated at 33 1C for a further 120 min. The cells were reacted with anti-HEF MAb (J14)
as a shaded area. Vertical and horizontal lines indicate the number of cells and ﬂuoresgene transfer by the generated WT-VLPs varied according to the
amount of pME18S/Met-CM2-YA. As a result, WT-VLPs generated
from the 293T cells transfected with 0.0315 mg pME18S/Met-CM2-
YA per 35-mm dish showed the most efﬁcient gene transfer to HMV-
II cells (data not shown).
Using the above-mentioned amount of pME18S/Met-CM2-YA
or pME18S/Met-CM2-N11A, WT-VLPs or N11A-VLPs were respec-
tively generated from the 293T cells. The amounts of the puriﬁed
VLPs generated from a given number of 293T cells were quanti-
ﬁed using Pierce 660 nm Protein Assay Kit (Thermo Fischer)
according to the manufacturer’s instructions. Three independent
experiments showed that the relative amount ratios of WT-VLPs
to N11A-VLPs were 1.0:1.03, 1.0:1.71, 1.0:1.04, which did not
reach statistical signiﬁcance between the two VLP populations
(p¼0.370). Therefore, we concluded that there was no difference
in the efﬁciency of VLP formation between the two constructs.
An equal amount of the puriﬁed VLPs was analyzed by immu-
noblotting using MAbs against HEF, NP and M1, and anti-CM2
serum (Fig. 4A and B). No signiﬁcant differences were observed in
the amounts of HEF and M1, whereas the amounts of NP in the
DCM2- and N11A-VLPs were smaller than that in the WT-VLPs
(Fig. 4A). To better quantify the amount of CM2 in WT-VLPs, the
sample was treated with N-glycanase and then analyzed by
Western blotting (Fig. 4B, left lane). The result showed that there
was no signiﬁcant difference in the amounts of CM2 incorporated
between WT-VLPs and N11A-VLPs. The amounts of GFP-vRNA in
the DCM2- and N11A-VLPs were 3% and 13% of that in the WT-
VLPs, respectively (po0.01) (Fig. 4C). Thus we concluded that the
CM2 glycosylation is involved in the genome packaging process,
since the amounts of virus components (HEF, NP, M1, CM2 and
GFP-vRNA) in N11A-VLP-producing 293T cells were comparable to
those in the WT-VLP-producing cells (data not shown).Reporter gene expression in VLP-infected HMV-II cells
CM2 has been shown to be involved in the uncoating process
(Furukawa et al., 2011). To examine whether the glycosylation of
CM2 affects the uncoating process, we analyzed the VLP-infected
HMV-II cells. First, attachment and internalization of the VLPs
were examined. As described previously (Furukawa et al., 2011), an
equal number of WT- and N11A-VLPs, which was calculated based
on the hemagglutinin units of the VLP preparations, was added to
HMV-II cells, followed by ﬂow cytometry. The histograms showedls infected with recombinant viruses were incubated at 4 1C for 30 min and then
and analyzed by ﬂow cytometry. The histogram frommock-infected cells is shown
cence intensities, respectively.
Fig. 4. Virus proteins and GFP-vRNA of VLPs. (A) The lysates of VLPs were subjected
to immunoblotting using MAbs against HEF (S16), NP (H31) and M1 (L2). (B) The
puriﬁedWT- or N11A-VLPs were incubated with (þ) or without (–) N-glycanase. The
VLPs were then subjected to immunoblotting using anti-M1 MAb (L2) and anti-CM2
serum. (C) RNA was extracted from a given amount of puriﬁed VLPs and subjected to
real-time PCR for quantiﬁcation of GFP-vRNA. The copy number of the GFP-vRNA in
the WT-VLPs was used for normalization. Data are expressed as the mean7SD in
three independent experiments. All comparisons between groups were statistically
evaluated (nnpo0.01). DCM2 indicates the CM2-deﬁcient VLPs (see text).
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as efﬁciently as that of the WT-VLPs (Fig. 5A).
Next, reporter gene expression in the VLP-infected cells was
examined. HMV-II cells were infected with VLPs so that the copy
number of GFP-vRNA included in WT-VLPs was equal to that in
N11A-VLPs, i.e. VLP preparations containing eight times as many
N11A-VLPs as WT-VLPs were infected. As a result, the GFP
expression level in the N11A-VLP-infected cells was reduced
compared with that in the WT-VLP-infected cells (Fig. 5B).
To quantify the reporter gene expression, WT- and N11A-VLPs
containing luciferase (Luc)-vRNA were generated and infected to
HMV-II cells; eight times as many N11A-VLPs as WT-VLPs were
used for infection. At 48 h p.i., the Luc activity in N11A-VLP-infected
cells was 15.674.2% of that in WT-VLP-infected cells (po0.01).
Furthermore, three independent experiments showed that the Luc
activity in N11A-VLP-infected cells was constantly lower than those
in WT-VLP-infected cells at 3–12 h p.i. (po0.01) (Fig. 5C). Taken
together, these ﬁndings highly suggest that the uncoating of the
N11A-VLPs occurs inefﬁciently than that of WT-VLP.
GFP-vRNA in VLP-infected HMV-II cells
Upon analysis of the roles of CM2 using the VLP system
(Furukawa et al., 2011), the localization of the incoming GFP-vRNAin the VLP-infected cells at the early phase of infection was exa-
mined by in situ hybridization, in order to obtain evidence for the
impaired uncoating of DCM2-VLP. However, the location (nuclear or
cytoplasm) of GFP-vRNA in the WT-VLP-infected HMV-II cells could
not be clearly observed due to the high background signals (data not
shown). In the present study, we quantiﬁed the incoming GFP-vRNA
transported to the nucleus of VLP-infected cells as reported pre-
viously (Furukawa et al., 2011).
As shown in Fig. 5D, there was no signiﬁcant difference in the total
copy number of GFP-vRNA in the cells just after the incubation for
30 min at 4 1C between WT- and N11A-VLP-infected cells, indicating
that an equal amount of GFP-vRNAs was used for infection. After
incubation at 33 1C for 60 min, the copy number of GFP-vRNA in
the nuclear fraction of WT-VLP-infected cells signiﬁcantly increased
(po0.05), whereas that of N11A-VLP-infected cells did not change.
Furthermore, after the 60min-incubation, a signiﬁcant difference in
the copy numbers in the nuclear fraction was observed between WT-
VLP- and N11A-VLP-infected cells (po0.05). These ﬁndings are
consistent with the idea that GFP-vRNA uncoated from the WT-
VLPs was efﬁciently transported to the nucleus whereas the transport
of the gene occurred less efﬁciently in the N11A-VLP-infected cells.
Taking these observations, we concluded that glycosylation of CM2 is
involved in the uncoating process.Discussion
To investigate the role(s) of CM2 in virus replication, we
generated recombinant inﬂuenza C viruses lacking CM2. However,
no infectious recombinants have been rescued to date (data not
shown). We then focused on the posttranslational modiﬁcation
sites of CM2, and generated rCM2-C65A, a recombinant inﬂuenza C
virus lacking CM2 palmitoylation (Muraki et al., 2011). The growth
of the rCM2-C65A virus was virtually identical to that of the
parental virus. As a result, we could not clarify the role(s) of CM2
using the recombinant lacking CM2 palmitoylation. In the present
study, therefore, we examined the effect of N-glycosylation of CM2
on the inﬂuenza C virus replication. A recombinant inﬂuenza C
virus lacking glycosylation of CM2 (rN11A) was successfully res-
cued, and we showed that rN11A was attenuated compared with
rWT (Fig. 1C), indicating that the glycosylation of CM2 is required
for the efﬁcient production of progeny viruses. Furthermore, a
series of analyses using N11A-VLPs enabled us to demonstrate that
the CM2 glycosylation is involved in the genome packaging and
uncoating processes (Figs. 4 and 5). Thus, the ﬁndings obtained in
the present study conﬁrmed and extended the previous observation
that CM2 is involved in the packaging and uncoating (Furukawa
et al., 2011), since we could provide evidence for the growth
difference of the mutant virus for the ﬁrst time.
Calnexin/calreticulin are involved in quality control of glyco-
proteins in the ER. The chaperons interact with newly synthesized
glycoproteins, promote their proper folding and assembly in the
ER, and the polypeptides properly folded and oligomerized are
transported to the Golgi apparatus (reviewed in Parodi, 2000). The
inﬂuenza A virus HA protein is controlled by calnexin/calreticulin
(Hebert et al., 1996, 1997) and the inﬂuenza C virus HEF lacking a
glycosylation site is defective in transport and trimerization
(Sugahara et al., 2001), whereas the inﬂuenza B virus NB lacking
glycosylation was properly expressed on the cell surface
(Williams and Lamb, 1988). In the present study, we showed that
CM2 synthesized in rN11A-infected cells was properly oligomer-
ized and transported to the cell surface (Fig. 2), which is
consistent with the previous observation that glycosylation is
not required for the transport of CM2 (Pekosz and Lamb, 1997).
Thus, it is less likely that calnexin/calreticulin are involved in CM2
folding and oligomerization.
Fig. 5. Analyses of VLP-infected cells. (A) Flow cytometry of HMV-II cells infected with VLPs. HMV-II cells infected withWT- or N11A-VLPs were treated as described in the legend of
Fig. 3. (B) Mock-, WT- and N11A-VLP-infected HMV-II cells were superinfected with AA/50, and then incubated for 48 h, followed by observation in a ﬂuorescent microscope
(magniﬁcation, 100). (C) HMV-II cells infected with VLPs containing luciferase-vRNA (see text) were lysed at the indicated periods after infection, and the luciferase activity in the
lysate was quantiﬁed. The luciferase activity detected in the WT-VLP-infected cell lysate at 12 h p.i is expressed as 100. (D) HMV-II cells infected with WT- or N11A-VLPs were
incubated at 4 1C for 30 min and then transferred to 33 1C, followed by incubation for a further 60 min. The cells were divided into cytoplasmic and nuclear fractions, and the GFP-
vRNA contained in the fractions was quantiﬁed by real-time PCR. The vertical line indicates the copy number of GFP-vRNA and the copy number in the cytoplasmic fraction of WT-
VLP-infected cells at 4 1C was used for normalization. The data obtained from four independent experiments are shown as the means7SD. All comparisons between groups were
statistically evaluated by using a paired t test (npo0.05; nnpo0.01; NS, not signiﬁcant).
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peptide in a given membrane protein can affect its protein proces-
sing, such as the US11 in human cytomegalovirus (Rehm et al.,
2001) and a coat protein of ﬁlamentous phage M13 (Russel and
Model, 1981). In the present study, we could provide evidence that
a mutation introduced in CM2 caused a decrease in the cleavage
efﬁciency of the precursor protein, P42. As mentioned in the Results
Section, a comparison of the amounts of M1, P42 (P44) and CM2
between rWT- and rN11A-infected cells showed that the conver-
sion of P42 into CM2 was delayed in rN11A-infected cells, suggest-
ing that P42 is cleaved less efﬁciently by the lack of glycosylation.
However, it is unlikely that the inefﬁcient cleavage of P42 in the
rN11A-infected cells affects the virus growth, since the synthesis
(Fig. 1A) and surface expression (Fig. 2B and D) of CM2 occurred
appropriately.
A comparison of the amounts of GFP-vRNA between WT- and
N11A-VLPs revealed that the glycosylation of CM2 affected genome
packaging (Fig. 4). To investigate whether the difference in the
packaging efﬁciency can be observed in the case of recombinants,
HMV-II cells were infected with rWT and rN11A at an MOI 5 and
progeny viruses generated from the cells were examined. The yield
of the rWT virus was 2–3 times as high as that of the rN11A virus,
but there was no signiﬁcant difference in the growth kinetics (data
not shown). This ﬁnding suggests that a subtle difference in the
virus yield shown in the high-MOI-infection experiment resulted ina considerable difference in the multi-step growth experiment
(Fig. 1C), and indicates that it is difﬁcult to clearly demonstrate
the difference in packaging efﬁciency using recombinant viruses.
The reduced packaging efﬁciency of N11A-VLPs may be related
to the structure and/or function of CM2. In the present study, no
unexpected mutations were found in the mutant M gene (data
not shown). Furthermore, based on our previous observations
(Muraki et al., 2011; Tada et al., 1998, Muraki and Hay, personal
communication), it is likely that both palmitoylation and phos-
phorylation occurs on glycosylation-deﬁcient CM2 molecules. We
therefore hypothesized that the loss of glycosylation affects the
structure of cytoplasmic region of the CM2 tetrameric molecule,
e.g. distance between each CM2 monomer, leading to the reduced
packaging efﬁciency. Alternatively, the reduced chloride ion
channel activity of the glycosylation-deﬁcient CM2 may also be
taken into account if the activity is linked to the genome
packaging (Hongo et al., 2004).
Takeda et al. (2002) reported that NP protein synthesis at the
early phase of infection occurred less efﬁciently in the cells
infected with inﬂuenza A viruses in which the uncoating process
was impaired. In the present study, to detect the difference in
virus protein synthesis at the early phase of infection, synthesis of
the NP protein in rWT- and rN11A-infected cells was examined,
but no difference was observed between the two cell populations
(see Results). Therefore, the Luc activity in the VLP-infected cells
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constantly lower than those in WT-VLP-infected cells (Fig. 5C), a
ﬁnding suggesting that the uncoating of N11A-VLPs occurred less
efﬁciently than did WT-VLPs. Moreover, the fact that the incom-
ing GFP-vRNA was transported to the nucleus less efﬁciently in
N11A-VLP-infected cells than WT-VLP-infected cells (Fig. 5D)
supports the idea that the uncoating of N11A-VLPs is impaired.
The glycosylation-deﬁcient CM2 has recently shown to possess
the ability to reduce pH of cytoplasm (Stewart and Pekosz, 2012)
although it remains unknown whether the activity of the
glycosylation-deﬁcient CM2 is similar to that of authentic CM2.
A number of studies showed that glycosylation of channel
proteins directly inﬂuences the gating characteristics and pH
sensitivity of the channel (Freeman et al., 2000; Montpetit et al.,
2009; Wirkner et al., 2008). Therefore, the possibility can be
proposed that the greater ability of authentic CM2 to reduce pH of
the virion interior than the glycosylation-deﬁcient CM2 would be
required for efﬁcient uncoating.Materials and methods
Cells and antibodies
293T, HMV-II, and LLC-MK2 cells were maintained in Dulbecco
modiﬁed Eagle medium with 10% fetal bovine serum, RPMI 1640
medium with 10% calf serum, and minimal essential medium with
5% fetal bovine serum and 5% calf serum, respectively (Muraki et al.,
2004, 2011; Nishimura et al., 1989). Monoclonal antibodies (MAbs)
against the HEF (J14, D37, S16), NP (H27, H31), and M1 (L2)
proteins of AA/50, and anti-CM2 serum were reported previously
(Hongo et al., 1994; Sugawara et al., 1991, 1993).
Plasmids
The Pol I plasmids for the expression of virus RNAs (vRNAs) of
AA/50 (pPolI/PB2, pPolI/PB1, pPolI/P3, pPolI/HEF, pPolI/NP, pPolI/M
and pPolI/NS), and the plasmids for the expression of the inﬂuenza
C virus proteins (pcDNA/PB2-AA, pcDNA/PB1-AA, pcDNA/P3-
AA, pME18S/HEF-AA, pCAGGS.MCS/NP-AA, pCAGGS.MCS/M1-AA,
pME18S/Met-CM2-YA, pME18S/NS1-YA, and pME18S/NS2-YA) were
reported previously (Muraki et al., 2004, 2007). The plasmid, pPolI/M-
CM2-N11A, used to generate vRNA encoding M1 and non-
glycosylated CM2, was generated by changing 833-AAC-835 of the
M gene to 833-GCC-835, based on pPolI/M. The plasmid, pME18S/
Met-CM2-N11A, for the expression of the non-glycosylated CM2
protein, was constructed based on pPolI/M-CM2-N11A. Details of the
primers and PCR protocols will be provided on request.
Generation of recombinant viruses by reverse genetics
A recombinant wild-type (rWT) virus, which has the consensus
sequences of AA/50, was generated by transfecting the above-
mentioned 16 plasmids into 293T cells as described previously
(Muraki et al., 2007). To generate a recombinant mutant virus
(rN11A), in which the asparagine at residue 11 of CM2 is mutated
to alanine, the pPolI/M-CM2-N11A was transfected into 293T cells
together with the other six Pol I plasmids and the nine expressing
plasmids. The culture medium of the transfected 293T cells was
collected at 90 h posttransfection (p.t.) and inoculated into the
amniotic cavity of 9-day-old embryonated chicken eggs. A stock
of the recombinant viruses was prepared as described previously
(Muraki et al., 2007, 2011). The nucleotide sequence of the rN11A
virus M gene was determined to ensure that no unwanted
mutations were present.Plaque titration
The infectious titers of the recombinants were determined
according to the procedure reported by Matrosovich et al. (2006)
and Muraki et al. (2011) using True BlueTM substrate (KPL).
Radioimmunoprecipitation
HMV-II cells infected with recombinant viruses were pulse-
labeled with [35S]methionine (ARC) (30 mCi/35 mm dish) for
20 min at 26 h postinfection (p.i.) in RPMI 1640 medium lacking
methionine, and chased for the indicated periods. Cells were then
disrupted in RIPA buffer (0.01 M Tris–HCl (pH 7.4), 0.15 M NaCl,
1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS) containing
cocktail of protease inhibitors (Sigma-Aldrich Biotechnology) and
immunoprecipitated with MAbs against HEF (J14), NP (H27) and
M1 (L2), or anti-CM2 serum. The immunoprecipitates obtained
were analyzed by SDS-PAGE on 17.5% gels containing 4 M urea,
and processed for ﬂuorography (Yokota et al., 1983).
Peptide-N-glycosidase F (N-glycanase) treatment
The immunoprecipitated CM2 proteins were digested with N-
glycanase (Roche) for 16 h at 37 1C as described previously
(Hongo et al., 1997), concentrated with Amicon Ultra-0.5 centri-
fugal ﬁlter unit (Millipore), and then analyzed by SDS-PAGE. The
puriﬁed VLPs (see below) were incubated with N-glycanase in the
presence of 0.4% NP-40, followed by immunoblotting.
Immunoblotting
Puriﬁed VLPs (see below), plasmid-transfected 293T cells, and
recombinant virus-infected HMV-II cells were resolved by SDS-
PAGE on 17.5% gels containing 4 M urea. After SDS-PAGE, immu-
noblotting was carried out as described previously (Muraki et al.,
2004) using the MAbs against HEF (S16), NP (H31) and M1 (L2),
and anti-CM2 serum. The proteins were detected by an enhanced
chemiluminescence Western blotting system (GE Healthcare)
according to the manufacturer’s instructions. Band intensities
were measured by ImageJ software, version 1.42 (Rasband, W.,
National Institutes of Health /http://rsb.info.nih.gov/ij/S).
Indirect immunoﬂuorescence
HMV-II cells grown on glass coverslips were infected with rWT
or rN11A, and incubated at 33 1C. The cells were ﬁxed in 10%
formalin, permeabilized with 0.2% Triton X-100, and analyzed by
indirect immunoﬂuorescence with anti-CM2 serum (primary
antibody) and ﬂuorescein isothiocyanate (FITC)-conjugated anti-
rabbit IgG (secondary antibody) (Vector). The trans-Golgi network
was stained with anti-g-adaptin MAb (100/3) (Sigma) and Alexa
Fluor 594 anti-mouse IgG (Molecular Probes). The cells were
examined by an LSM710 confocal laser scanning microscope (Carl
Zeiss).
Detection of cell surface proteins
To detect virus proteins expressed on the infected cells, cell
surface biotinylation was performed as described previously
(Muraki and Hay, 2009). Brieﬂy, monolayered HMV-II cells
infected with the recombinants were washed with ice-cold PBS
at 26 h p.i., and exposed to 0.5 mg/ml sulfo-NHS-LC-biotin
(Pierce) in PBS for 30 min on ice. The reaction was stopped by
rinsing the cells twice with 100 mM glycine in ice-cold PBS, and
the cells were lysed in 450 ml of RIPA buffer containing cocktail of
protease inhibitors and incubated for 30 min on ice. The resulting
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supernatants (420 ml) were incubated for 60 min at room tem-
perature with streptavidin–agarose (Pierce). The obtained pre-
cipitates (biotinylated proteins) and whole cell lysates (30 ml)
were subjected to SDS-PAGE, followed by immunoblotting.
Flow cytometry of HMV-II cells infected with viruses and VLPs
Monolayered HMV-II cells were trypsinized using Accutase
(Sigma-Aldrich) and then added to the amniotic ﬂuids containing
recombinant viruses or the supernatants containing VLPs. After
incubation on ice for 30 min, an aliquot of the cells was trans-
ferred to 33 1C and incubated for 120 min. The cells were then
washed twice with Hanks’ balanced salt solution and incubated
with anti-HEF MAb J14 (primary antibody) and FITC-conjugated
anti-mouse IgG antibody (secondary antibody) (Jackson Immu-
noresearch). The cells were subjected to ﬂow cytometry using a
FACSCalibur instrument (Becton Dickinson).
Generation and puriﬁcation of VLPs
To generate WT-VLPs, 293T cells were transfected with the
pPolI/NP-AA.GFP() (Muraki et al., 2004) and the nine expressing
plasmids described above. For the generation of VLPs possessing
non-glycosylated CM2 (N11A-VLPs), 293T cells were transfected
with the same combination of plasmids, with the exception of the
use of pME18S/Met-CM2-N11A instead of pME18S/Met-CM2-YA.
To generate CM2-deﬁcient VLPs (DCM2-VLPs), pME18S was trans-
fected instead of pME18S/Met-CM2-YA. The VLPs in the culture
medium were collected, puriﬁed and suspended in 10% glycerol in
PBS as described previously (Furukawa et al., 2011). To generate
VLPs containing luciferase (Luc)-vRNA, pPolI/NP-AA.Luc() (Muraki
et al., 2004) was transfected instead of pPolI/NP-AA.GFP(). Prior to
the experiments, we re-evaluated the amount of the pME18S/Met-
CM2-YA for transfection, and as a result the amount was deter-
mined to be 0.0315 mg per a 35-mm dish for the generation of WT-
VLPs (see results).
Infection of HMV-II cells with VLPs
The puriﬁed VLPs were treated with N-tosyl-L-phenylalanyl
chloromethyl ketone (TPCK)-treated trypsin (20 mg/ml) at 37 1C
for 10 min, followed by the addition of soybean trypsin inhibitor.
The monolayered HMV-II cells were infected with the VLPs at
33 1C for 60 min and subsequently infected with the helper virus
(AA/50) at a multiplicity of infection (MOI) of 5, and incubated for
the indicated periods. For the quantiﬁcation of incoming GFP-
vRNA, the helper virus was not used for infection to avoid the
replication of GFP-vRNA in the infected cells. GFP-positive HMV-II
cells were observed under a ﬂuorescent microscope (Olympus
IX70) and photographed. Luciferase (Luc) activity in the VLP-
infected cells was measured using a GloMax 96 Microplate
Luminometer (Promega).
RNA extraction, reverse transcription, and real-time PCR
The RNAs were extracted from the plasmid-transfected 293T
cells, puriﬁed VLPs, and nuclear and cytoplasmic fractions of VLP-
infected HMV-II cells (see below) using an RNeasy Mini Kit
(Qiagen). The RNA preparation was treated with DNase I (Takara),
cleaned, and then reverse transcribed using a primer for the GFP
gene (50–ATGGTGAGCAAGGGCGAGGAGCTGTTC–30). Quantiﬁca-
tion of GFP-vRNA by real-time PCR was carried out using Power
SYBR Green PCR Master Mix Kit (Applied Biosystems) in an ABI
Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems).
The standard curve was calculated based on the results using aseries of 10-fold dilutions of pPolI/NP-AA.GFP() as a template.
As a loading control of RNAs extracted from the cells, b-actin
mRNA was quantiﬁed by real-time PCR as described previously
(Furukawa et al., 2011).
Cell fractionation
VLP-infected HMV-II cells were subjected to fractionation as
described previously (Furukawa et al., 2011; Sugawara et al., 2006).
Brieﬂy, HMV-II cells mildly solubilized with RSB buffer (10 mM
Tris–HCl, 100 mMNaCl, 1.5 mMMgCl2, pH 8.0) containing 0.3% NP-
40 for 30 min at 0 1C were divided into two fractions by centrifuga-
tion at 1200 g for 5 min at 4 1C. The precipitate was washed twice
with the RSB buffer containing 0.3% NP-40 and then used as the
nuclear fraction. The supernatant was re-centrifuged at 10,000 g
for 5 min at 4 1C, and the resulting supernatant was used as the
cytoplasmic fraction.
Statistical analysis
All functional tests were carried out independently at least three
times. Data between groups were analyzed using a paired t-test. A p
value of less than 0.05 was considered statistically signiﬁcant.Acknowledgments
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